Provided by Tiger Fintech (Singapore) Pte. Ltd.

MaxCyte Inc

2.66
-0.0100-0.37%
Volume:2.13M
Turnover:5.67M
Market Cap:282.79M
PE:-6.79
High:2.77
Open:2.64
Low:2.60
Close:2.67
Loading ...

BlackRock Adjusts Stake in MaxCyte, Influencing Voting Rights

TIPRANKS
·
18 Dec 2024

MaxCyte, Inc. Announces Change in Major Holdings by BlackRock

TIPRANKS
·
11 Dec 2024

MaxCyte Announces Change in Major Shareholdings

TIPRANKS
·
11 Dec 2024

Stifel Nicolaus Reaffirms Their Buy Rating on MaxCyte (MXCT)

TIPRANKS
·
10 Dec 2024

MaxCyte Shares Surge On Boost to Revenue-Growth Outlook

Dow Jones
·
10 Dec 2024

MaxCyte’s Strategic Growth and Cost Efficiency Drive Buy Rating

TIPRANKS
·
10 Dec 2024

MaxCyte to reduce workforce by 15% following internal review

TIPRANKS
·
09 Dec 2024

MaxCyte raises FY24 core business revenue view to 6%-8% from flat to up 5%

TIPRANKS
·
09 Dec 2024

MaxCyte Reduces 15% of Workforce, Raises 2024 Revenue Guidance

MT Newswires Live
·
09 Dec 2024

BRIEF-Maxcyte Announces Streamlined Operations And Raises 2024 Revenue Guidance

Reuters
·
09 Dec 2024

MaxCyte, Inc. MaxCyte, Inc. - Mxcr - MaxCyte Streamlines Operations and Raises Guidance

THOMSON REUTERS
·
09 Dec 2024

MaxCyte Inc - Cuts 21 Positions, 15% of Global Workforce

THOMSON REUTERS
·
09 Dec 2024

MaxCyte Inc - Expects $5.8 Million Cost Savings in 2025

THOMSON REUTERS
·
09 Dec 2024

MaxCyte Inc - Raises 2024 Core Revenue Guidance to 6%-8% Growth

THOMSON REUTERS
·
09 Dec 2024

MaxCyte Inc: Raising Its Full-Year 2024 Core Revenue Guidance to Project 6% to 8% Growth Compared to 2023

THOMSON REUTERS
·
09 Dec 2024

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

THOMSON REUTERS
·
09 Dec 2024

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

GlobeNewswire
·
09 Dec 2024

MaxCyte’s Voting Rights Shift with BlackRock Acquisition

TIPRANKS
·
28 Nov 2024

This MaxCyte Insider Increased Their Holding In The Last Year

Simply Wall St.
·
21 Nov 2024

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

GlobeNewswire
·
13 Nov 2024